US Court dismisses lawsuit against the FDA

RNS Number : 0383A
AstraZeneca PLC
26 March 2012
 



US COURT DENIES PRELIMINARY INJUNCTION APPLICATION AGAINST THE FDA AND DISMISSES ASTRAZENECA'S LAWSUIT WITHOUT PREJUDICE

 

 

On 23 March 2012, the US District Court for the District of Columbia issued an opinion and order in AstraZeneca's lawsuit against the US Food and Drug Administration (FDA) regarding final marketing approval of generic quetiapine. The Court denied the company's request for a preliminary injunction and dismissed the lawsuit without prejudice. 

 

Notwithstanding the Court's decision, the company continues to believe strongly in the merits of its position and is evaluating its options. 

 

 

NOTES TO EDITORS

 

About the lawsuit and the Citizen Petitions

On 12 March 2012, AstraZeneca filed a lawsuit against the FDA to overturn the FDA's denial on 7 March 2012 of the company's Citizen Petitions with regard to SEROQUEL® (quetiapine fumarate) tablets and SEROQUEL XR® (quetiapine fumarate) extended release tablets. 

 

In its lawsuit, AstraZeneca sought an injunction barring the FDA from granting final marketing approval of generic quetiapine until 2 December 2012 when regulatory exclusivity expires on important clinical trial data, or, alternatively, at least until a federal court had a meaningful opportunity to review imminent FDA action regarding the pending generic marketing applications.

 

On 9 September 2011 AstraZeneca filed a Citizen Petition with the US Food and Drug Administration (FDA) for each of SEROQUEL and SEROQUEL XR, requesting the FDA withhold finally approving any generic quetiapine product that omits from its labelling certain hyperglycaemia and suicidality warning language that FDA required AstraZeneca to include in the labelling for SEROQUEL and SEROQUEL XR. Data associated with the hyperglycaemia warning language at issue is protected by marketing exclusivity periods expiring as late as 2 December 2012. In the Citizen Petitions, AstraZeneca raised important issues regarding labelling requirements for generic copies of innovative medicines, as well as data exclusivity rights granted to innovative companies that conduct new clinical trials.

 

 

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.

 

 

CONTACTS

 

Media Inquiries US

Tony Jewell                                 +1 302 885 4594

Julia Walker                                +1 302 885 5172

 

Media Enquiries

Esra Erkal-Paler                         +44 20 7604 8030
Sarah Lindgreen                         +
44 20 7604 8033

 

Investor Enquiries UK

James Ward-Lilley                     +44 20 7604 8122    mob: +44 7785 432613

Karl Hård                                     +44 20 7604 8123   mob: +44 7789 654364

Nicklas Westerholm                   +44 20 7604 8124   mob: +44 7585 404950

 

Investor Enquiries US

Ed Seage                                    +1 302 886 4065   mob: +1 302 373 1361
Jorgen Winroth                           +1 212 579 0506   mob: +1 917 612 4043

 

 

26 March 2012

 

 

-ENDS -

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDMGZFKVDGZZG

Companies

AstraZeneca (AZN)
UK 100